Pediatric Hypertension Management
Initial Treatment
- The American Academy of Pediatrics recommends first-line medications for pediatric hypertension, including ACE inhibitors, ARBs, long-acting calcium channel blockers, or thiazide diuretics, for children with persistent hypertension despite lifestyle modifications, left ventricular hypertrophy, symptomatic hypertension, stage 2 hypertension, or hypertension associated with chronic kidney disease or diabetes mellitus 1
- For most children with primary hypertension, ACE inhibitors, ARBs, long-acting calcium channel blockers, or thiazide diuretics are recommended as initial treatment 1
- For African American children, consideration should be given to starting with a higher initial dose of ACE inhibitor or starting with a thiazide diuretic or long-acting calcium channel blocker 1
Special Populations
- For children with hypertension and chronic kidney disease, proteinuria, or diabetes mellitus, ACE inhibitors or ARBs are recommended as first-line treatment, unless contraindicated 1
- Adolescent females of childbearing potential should be considered for calcium channel blockers or β-blockers, as ACE inhibitors and ARBs are contraindicated in pregnancy 1
Blood Pressure Targets
- For children <13 years, the target blood pressure is below the 90th percentile, while for adolescents ≥13 years, the target is <130/80 mm Hg 2, 3
Medication Management
- Medication therapy should be initiated at the low end of the dosing range and increased every 2-4 weeks until blood pressure is controlled, maximum dose is reached, or adverse effects occur 1
- Follow-up should occur every 4-6 weeks until blood pressure normalizes, and a second agent should be added if blood pressure is not controlled with a single agent 1
Guideline Recommendations
- The 2017 American Academy of Pediatrics Clinical Practice Guideline provides evidence-based recommendations for pediatric hypertension management, developed using a strict evidence-based approach and aligning with adult hypertension guidelines where appropriate 1, 3
- β-blockers are not recommended as initial treatment in children due to their expanded adverse effect profile and lack of association with improved outcomes compared to other agents 1